InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,717.84
(
1.77%
)
US TECH 100
19,437.50
(
3.08%
)
Dow Jones
42,034.80
(
1.28%
)
Brent Oil
74.22
(
2.54%
)
Bitcoin
63,574.03
(
3.09%
)
Post# of 46542
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jxyzobrien

Send PM Follow Ignore
Followers 83
Posts 27220
Boards Moderated 1
Alias Born 04/05/2007

jxyzobrien

Re: haha11 post# 40746

Thursday, 10/19/2017 10:06:47 AM

Thursday, October 19, 2017 10:06:47 AM

Post# of 46542
Gild
Gilead's purchase of Kite Pharma poised to pay off
Gilead Sciences Inc.'s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite's flagship cell-therapy treatment for advanced lymphoma patients.
The therapy, known as a Car-T treatment, uses genetically engineered T-cells to attack the blood cancer. It is the second such therapy to get a regulatory green light, after Novartis AG's (NOVN.EB) Car-T drug Kymriah was approved in late August.

earnings the 26
estimates increasing during the quarter
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up